Ligand Pharmaceuticals Inc
LGND· Nasdaq
LGNDLigand Pharmaceuticals Inc
Filed Feb 26, 2016 · 10-K · 57 days after period end · 0000886163-16-000149
| Metric | Q4 2015 | Q4 2012 | Q4 2011dderived from reported figures | Q4 2010 |
|---|---|---|---|---|
| Revenue | $21.19M | $6.38M | $13.64M | $12.94M |
| Net Income | $6.34M | -$194.00K | $1.06M | $4.69M |
| EPS Diluted | $0.29 | -$0.01 | — | $0.24 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
ended Dec 31, 2015 · filed Feb 26, 2016 · 57 d after period end
